|
Mutation Information
|
Mutation Site
|
A181T |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.N236T+rt.A181T;rt.M250L+rt.N236T+rt.A181T;rt.A181T+rt.I169V |
|
Relevant Drug
|
adefovir dipivoxil (ADV);lamivudine (LAM) |
|
Country
|
China |
Literature Information
|
PubMed PMID
|
28300730
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2017 |
|
Journal
|
Antiviral therapy |
|
Title
|
The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy. |
|
Author
|
Shan M,Shen Z,Sun H,Zheng J,Zhang M |
|
Evidence
|
The substitution of rtA181T is another frequently detected primary mutation, conferring resistance to LMV and ADV, and leading to a premature stop codon sW172* in the corresponding S protein, while no significant difference in serum HBsAg level was observed in patients with or without this mutation.
|
|
|
HBV Mutation Detail Information